Becnel Melody R, Lee Hans C
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 429, Houston, TX, 77030, USA.
Ther Adv Hematol. 2020 Dec 14;11:2040620720979813. doi: 10.1177/2040620720979813. eCollection 2020.
Belantamab mafodotin (belamaf) is a first-in-class anti-B-cell maturation antigen (BCMA) antibody-drug conjugate (ADC) that recently gained regulatory approval for the treatment of relapsed and/or refractory multiple myeloma (RRMM) patients who have received at least four prior therapies including an anti-CD38 monoclonal antibody (mAb), a proteasome inhibitor (PI), and an immunomodulatory drug (IMiD). As the first BCMA-targeted therapy to be approved in multiple myeloma along with its "off-the-shelf" outpatient administration, belamaf addresses a significant unmet need in RRMM that is refractory to IMiD, PI, and anti-CD38 mAb therapy, otherwise known as triple-class refractory myeloma. Belamaf is also associated with frequent corneal ocular adverse events, which represents a unique toxicity in multiple myeloma therapeutics, and its administration requires a multidisciplinary approach with oncologists and eye care specialists to safely and effectively manage patients on belamaf therapy. In this review, we discuss the preclinical and clinical data leading to the regulatory approval of belamaf, the monitoring and mitigation strategies of corneal ocular adverse events, and its current and future role in the RRMM treatment landscape.
贝兰他单抗莫福汀（belamaf）是首个抗B细胞成熟抗原（BCMA）的抗体药物偶联物（ADC），最近已获得监管批准，用于治疗复发和/或难治性多发性骨髓瘤（RRMM）患者，这些患者此前至少接受过四种治疗，包括一种抗CD38单克隆抗体（mAb）、一种蛋白酶体抑制剂（PI）和一种免疫调节药物（IMiD）。作为多发性骨髓瘤中首个获批的靶向BCMA疗法，以及其“即用型”门诊给药方式，belamaf满足了RRMM中一个重大的未满足需求，即对IMiD、PI和抗CD38 mAb治疗难治的情况，也就是所谓的三重难治性骨髓瘤。Belamaf还常伴有角膜眼部不良事件，这在多发性骨髓瘤治疗中是一种独特的毒性，其给药需要肿瘤学家和眼科护理专家采用多学科方法，以安全有效地管理接受belamaf治疗的患者。在本综述中，我们讨论了导致belamaf获得监管批准的临床前和临床数据、角膜眼部不良事件的监测和缓解策略，以及其在RRMM治疗格局中的当前和未来作用。
